G2GBio secures operating funds through paid-in capital increase of 75 billion KRW

G2G Bio has decided to conduct a paid-in capital increase to raise approximately 75 billion Korean won in operating funds. The company plans to use this to ensure funds for facility investments and operational purposes.

According to an announcement released by G2G Bio on the 23rd, 817,869 new shares will be issued through a third-party allocation, with a price of 91,700 Korean won per share. The recipients of this capital increase are selected as NH-Square-Life New Technology Investment Portfolio, KBSBI Global Cutting-Edge Strategic Private Equity Partnership, and KB Securities. They are expected to be allocated 136,314 shares, 81,788 shares, and 27,262 shares respectively.

The company stated that through this paid-in capital increase, it plans to secure stable operational funds while promoting future facility investments. This is viewed as a strategic move aimed at creating the necessary investment conditions for long-term growth. The choice of this financing method can be interpreted as an effort to enhance operational flexibility and respond agilely to the rapidly changing market environment.

As a publicly listed company on KOSDAQ, a stock market familiar to the public, the company intends to strengthen its capital through this capital increase to ultimately enhance corporate value. The market is closely watching whether G2G Bio’s decision will have a positive impact on the company’s growth model. Such capital mobilization strategies are likely to serve as reference cases for other listed companies in the future.

Looking ahead, the way G2G Bio utilizes its funds and its actual operational results are expected to be key factors in gaining investor trust. If the company’s strategic capital operations succeed, it is not unlikely that more companies will consider similar financing methods as an opportunity.